Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Foreign free riders and the high price of US medicines.

Literature DB >> 16239695

Foreign free riders and the high price of US medicines.

Donald W Light¹, Joel Lexchin.

Abstract

Mesh：

Year: 2005 PMID： 16239695 PMCID： PMC1261198 DOI： 10.1136/bmj.331.7522.958

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

4 in total

1. No exit and the organization of voice in biotechnology and pharmaceuticals.

Authors: Donald W Light; Ramón Castellblanch; Pablo Arredondo; Deborah Socolar
Journal: J Health Polit Policy Law Date: 2003 Apr-Jun Impact factor: 2.265

2. Industrial interests versus public health: the gap is growing.

Authors:
Journal: Prescrire Int Date: 2004-04

3. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.

Authors: David J Gross; Stephen W Schondelmeyer; Susan O Raetzman
Journal: Issue Brief (Public Policy Inst (Am Assoc Retired Pers)) Date: 2004-06

Review 4. Pricing medicines: theory and practice, challenges and opportunities.

Authors: Nigel Gregson; Keiron Sparrowhawk; Josephine Mauskopf; John Paul
Journal: Nat Rev Drug Discov Date: 2005-02 Impact factor: 84.694

4 in total

8 in total

1. US pharmaceutical innovation in an international context.

Authors: Salomeh Keyhani; Steven Wang; Paul Hebert; Daniel Carpenter; Gerard Anderson
Journal: Am J Public Health Date: 2010-04-19 Impact factor: 9.308

2. Health policy: Putting a price on cancer.

Authors: Richard Sullivan; Ajay Aggarwal
Journal: Nat Rev Clin Oncol Date: 2016-02-09 Impact factor: 66.675

Review 3. Views on the ethical struggle for universal, high quality, affordable health care and its relevance for gerontology.

Authors: George M Martin
Journal: Exp Gerontol Date: 2016-04-19 Impact factor: 4.032

Foreign free riders and the high price of US medicines.

1. No exit and the organization of voice in biotechnology and pharmaceuticals.

2. Industrial interests versus public health: the gap is growing.

3. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.

Review 4. Pricing medicines: theory and practice, challenges and opportunities.

1. US pharmaceutical innovation in an international context.

2. Health policy: Putting a price on cancer.

Review 3. Views on the ethical struggle for universal, high quality, affordable health care and its relevance for gerontology.

4. The Challenge of High Drug Prices in America: Cost Disclosure in Direct-to-Consumer Advertising May Offer a Solution.

Review 5. Effectiveness, safety and costs of orphan drugs: an evidence-based review.

6. Affordability of medicines in the European Union.

7. Public sector financial support for late stage discovery of new drugs in the United States: cohort study.

8. Patients not patents: Drug research and development as a public enterprise.